drugset / Trial / NCT00004108

DX-8951f in Treating Patients With Liver Cancer

NCT00004108

Phase 2 Completed Daiichi Sankyo
Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DX-8951f in treating patients who have liver cancer.

Timeline

Start
1999-09
Primary completion
2005-04
Completion
2005-04

Drugs

EvaluationDrugModalityDoseRoute
Subject exatecan Small molecule Intravenous

Indications